Targeted DiversiTy T-cells

About Geneius Biotechnology

Geneius Biotechnology is a private, pre-revenue biotech based in San Diego, advancing a novel platform of non-genetically engineered, autologous T-cell therapies for cancer. Its proprietary Targeted DiversiTy™ and SMAR-T™ manufacturing platform aims to produce T cells with superior killing, homing, and duration against solid and liquid tumors, starting with EBV+ cancers. The company highlights compelling academic proof-of-concept data, a scalable manufacturing process, and a potential cost and accessibility advantage over current CAR-T therapies as key differentiators as it moves toward initial clinical trials.

About Geneius Biotechnology

Geneius Biotechnology is a private, pre-revenue biotech based in San Diego, advancing a novel platform of non-genetically engineered, autologous T-cell therapies for cancer. Its proprietary Targeted DiversiTy™ and SMAR-T™ manufacturing platform aims to produce T cells with superior killing, homing, and duration against solid and liquid tumors, starting with EBV+ cancers. The company highlights compelling academic proof-of-concept data, a scalable manufacturing process, and a potential cost and accessibility advantage over current CAR-T therapies as key differentiators as it moves toward initial clinical trials.

Therapeutic Areas